Avtor/Urednik		Kocjan, Tomaž; Jensterle Sever, Mojca; Preželj, Janez
Naslov		Strokovna stališča Združenja endokrinologov Slovenije o obravnavi glukokortikoidne osteoporoze
Prevedeni naslov		A position statement of the Slovenian endocrine society on the management of glucocorticoid-induced osteoporosis
Tip		članek
Vol. in št.		Letnik 87, št. 9/10
Leto izdaje		2018
Obseg		str. 453-460
ISSN		1318-0347 - Zdravniški vestnik : glasilo Slovenskega zdravniškega društva : Slovenian medical journal
Jezik		slv
Abstrakt		Treatment with glucocorticoids is the most common cause of secondary osteoporosis. Glucocorticoid osteoporosis is characterised by a very rapid decline in bone mineral density with a rapid increase in the fracture risk, so at the time of glucocorticoid prescription the patient's risk of fracture should be assessed and advice regarding healthy lifestyle, intake of calcium, vitamin D and protein should be given. If indicated, bone-protective agents are introduced as well to increase bone mineral density and reduce vertebral fractures risk. Bisphosphonates are the first choice, while teriparatide is reserved for patients with higher fracture risk who have already sustained a fracture.
Proste vsebinske oznake		bisfosfonati glukokortikoidi osteoporozni zlomi bisphosphonates glucocorticoids osteoporotic fractures